生活方式干预在2型糖尿病临床防治中的新角色

doi:10.3969/j.issn.1006-5725.2025.17.001

摘要/Abstract

摘要：

2型糖尿病（diabetes mellitus type 2， T2DM）的患病人数正随着肥胖发病率的逐年递增而快速增加，对全球医疗系统造成严重负担。近年来，生活方式干预（lifestyle intervention， LSI）通过有效减重实现T2DM防治的潜能被发掘，其在临床防治T2DM的重要性与日俱增，但要实现有效的LSI防治T2DM从理论到临床应用的跨越，仍面临着诸多挑战，例如缺乏专业指导、患者依从性差及体质量反弹等问题。尽管如此，鉴于LSI在T2DM防治领域、众多循证医学研究结果的卓越表现以及理论上的可行性，从“以药为主”到“以LSI为主”的理念转变为临床上T2DM的防治带来了新的希望与挑战。

关键词: 生活方式干预, 2型糖尿病, 减重

Abstract:

The number of patients with type 2 diabetes （T2DM） is rapidly increasing with the annual rise in obesity rates， placing a serious burden on healthcare systems worldwide. In recent years， the potential of lifestyle interventions（LSI） to prevent and treat T2DM through effective weight loss has been recognized， and their importance in the clinical prevention and treatment of T2DM has grown. However， there are still many challenges to be overcome in order to achieve effective LSI prevention and control of T2DM， from theory to clinical application， including a lack of professional guidance， poor patient compliance， and weight regain. Nevertheless， given the outstanding results of numerous evidence-based medical studies on lifestyle interventions in the prevention and treatment of T2DM， as well as their theoretical feasibility，the shift from a “drug-centric” to an “LSI-centric” bringing new hope and new challenges to the clinical prevention and treatment of T2DM.

Key words: lifestyle Intervention, Type 2 diabetes, weight loss

中图分类号:

R587.1

宁潇雨,陈小燕. 生活方式干预在2型糖尿病临床防治中的新角色[J]. 实用医学杂志, 2025, 41(17): 2611-2616.

Xiaoyu NING,Xiaoyan CHEN. The new role of lifestyle interventions in the clinical prevention and treatment of type 2 diabetes[J]. The Journal of Practical Medicine, 2025, 41(17): 2611-2616.

参考文献 42

[1]	The Lancet. Diabetes： a defining disease of the 21st century［J］. Lancet， 2023， 401（10394）：2087. doi:10.1016/s0140-6736(23)01296-5 doi: 10.1016/s0140-6736(23)01296-5
[2]	LAURYN STAFFORD， LIANE ONG. Global diabetes cases on pace to soar to 1.3 billion people in the next 3 decades， new study finds ［M］. 2023-07-19. . doi:10.64628/aai.3qd6dygme doi: 10.64628/aai.3qd6dygme
[3]	CURRENTI W， LOSAVIO F， QUIETE S， et al. Comparative Evaluation of a Low-Carbohydrate Diet and a Mediterranean Diet in Overweight/Obese Patients with Type 2 Diabetes Mellitus： A 16-Week Intervention Study ［J］. Nutrients， 2023， 16（1）：95. doi:10.3390/nu16010095 doi: 10.3390/nu16010095
[4]	ROSENFELD R M， GREGA M L， KARLSEN M C， et al. Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults： A Clinical Practice Guideline From the American College of Lifestyle Medicine ［J］， Am J Lifestyle Med， 2025， 19（2 ）： 10S-131S. doi:10.1177/15598276251325441 doi: 10.1177/15598276251325441
[5]	KLEIN S， GASTALDELLI A， YKI-JäRVINEN H， et al. Why does obesity cause diabetes？［J］. Cell Metab， 2022， 34（1）： 11-20. doi:10.1016/j.cmet.2021.12.012 doi: 10.1016/j.cmet.2021.12.012
[6]	LU X， XIE Q， PAN X， et al. Type 2 diabetes mellitus in adults： Pathogenesis， prevention and therapy ［J］. Signal Transduct Target Ther， 2024， 9（1）： 262. doi:10.1038/s41392-024-01951-9 doi: 10.1038/s41392-024-01951-9
[7]	LINGVAY I， SUMITHRAN P， COHEN R V， et al. Obesity management as a primary treatment goal for type 2 diabetes： Time to reframe the conversation ［J］. Lancet， 2022， 399（10322）： 394-405. doi:10.1016/s0140-6736(21)01919-x doi: 10.1016/s0140-6736(21)01919-x
[8]	VODOVOTZ Y， BARNARD N， HU F B， et al. Prioritized Research for the Prevention， Treatment， and Reversal of Chronic Disease： Recommendations From the Lifestyle Medicine Research Summit ［J］. Front Med （Lausanne）， 2020， 7： 585744. doi:10.3389/fmed.2020.585744 doi: 10.3389/fmed.2020.585744
[9]	KNOWLER W C， FOWLER S E， HAMMAN R F， et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study ［J］. Lancet， 2009， 374（9702）： 1677-1686. doi:10.1016/s0140-6736(09)61457-4 doi: 10.1016/s0140-6736(09)61457-4
[10]	LI G， ZHANG P， WANG J， et al. Cardiovascular mortality， all-cause mortality， and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study： A 23-year follow-up study ［J］. Lancet Diabetes Endocrinol， 2014， 2（6）： 474-480. doi:10.1016/s2213-8587(14)70057-9 doi: 10.1016/s2213-8587(14)70057-9
[11]	GOYAL MEHRA C， RAYMOND A M， PRABHU R. A personalized multi-interventional approach focusing on customized nutrition， progressive fitness， and lifestyle modification resulted in the reduction of HbA1c， fasting blood sugar and weight in type 2 diabetes： A retrospective study ［J］. BMC Endocr Disord， 2022， 22（1）： 290. doi:10.1186/s12902-022-01212-2 doi: 10.1186/s12902-022-01212-2
[12]	CHAI X， WANG Y， YIN X， et al. Effects of lifestyle interventions on the prevention of type 2 diabetes and reversion to normoglycemia by prediabetes phenotype： A systematic review and meta-analysis of randomized controlled trials ［J］. Diabetes Metab Syndr， 2025， 19（1）： 103184. doi:10.1016/j.dsx.2025.103184 doi: 10.1016/j.dsx.2025.103184
[13]	LU Q， CHEN J， LI R， et al. Healthy lifestyle， plasma metabolites， and risk of cardiovascular disease among individuals with diabetes ［J］. Atherosclerosis， 2023， 367： 48-55. doi:10.1016/j.atherosclerosis.2022.12.008 doi: 10.1016/j.atherosclerosis.2022.12.008
[14]	TRIPATHI P， SHARMA B， KADAM N， et al. Improvement in symptoms of anxiety and depression in individuals with type 2 diabetes： Retrospective analysis of an intensive lifestyle modification program ［J］. BMC Psychiatry， 2024， 24（1）： 714. doi:10.1186/s12888-024-06130-2 doi: 10.1186/s12888-024-06130-2
[15]	JAMES N， GIBBONS K， AGBOYIBOR K， et al. Tackling the （un）affordability of medicines for cardiometabolic risk factors worldwide： A call to action［J］. BMJ Glob Health， 2025， 10（7）： e019824. doi:10.1136/bmjgh-2025-019824 doi: 10.1136/bmjgh-2025-019824
[16]	BARTHILD D， LI J， BASU A. Patient out-of-pocket costs for type 2 diabetes medications when aging into Medicare［J］. JAMA Netw Open， 2024， 7（7）： e2420724. doi:10.1001/jamanetworkopen.2024.20724 doi: 10.1001/jamanetworkopen.2024.20724
[17]	ALFAIFI A. Association between non-pharmacological therapy and healthcare use and expenditure of patients with diabetes mellitus［J］. Saudi Pharm J， 2023， 31（8）： 101685. doi:10.1016/j.jsps.2023.06.018 doi: 10.1016/j.jsps.2023.06.018
[18]	EZURA M， SAITO S， ISHIZAWA M， et al. Estimation of the effects and costs of lifestyle intervention and treatment with voglibose in the Japanese prediabetic population： A cost-effectiveness analysis［J］. Value Health Reg Issues， 2025， 47： 101098. doi:10.1016/j.vhri.2025.101098 doi: 10.1016/j.vhri.2025.101098
[19]	HESKETH K， LOW J， ANDREWS R， et al. Mobile health biometrics to enhance exercise and physical activity adherence in type 2 diabetes （MOTIVATE-T2DM）： A decentralised feasibility randomised controlled trial delivered across the UK and Canada［J］. BMJ Open， 2025， 15（3）： e092260. doi:10.1136/bmjopen-2024-092260 doi: 10.1136/bmjopen-2024-092260
[20]	MA J， WAN X， WU B. The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting［J］. J Diabetes Res， 2020， 2020： 7410797. doi:10.1155/2020/7410797 doi: 10.1155/2020/7410797
[21]	顾东风，翁建平，鲁向锋. 中国健康生活方式预防心血管代谢疾病指南［J］. 中国循环杂志， 2020， 35（3）： 209-230.
[22]	DIABETES PREVENTION PROGRAM RESEARCH G. The Diabetes Prevention Program （DPP）： Description of lifestyle intervention［J］. Diabetes Care， 2002， 25（12）： 2165-2171. doi:10.2337/diacare.25.12.2165 doi: 10.2337/diacare.25.12.2165
[23]	ZHANG P， ATKINSON K M， BRAY G A， et al. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes： Results From the Action for Health in Diabetes （Look AHEAD） Study［J］. Diabetes Care， 2021， 44（1）： 67-74.
[24]	LINDSTRöM J， PELTONEN M， ERIKSSON J G， et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study［J］. Diabetes Care， 2008， 31（5）： 857-862. doi:10.2337/dc07-2162 doi: 10.2337/dc07-2162
[25]	HU G， LIU H， LENG J， et al. Effects of a Lifestyle Intervention in Young Women with GDM and Subsequent Diabetes［J］. Nutrients， 2022， 14（24）：5232. doi:10.3390/nu14245232 doi: 10.3390/nu14245232
[26]	PEñA A， OLSON M L， HOOKER E， et al. Effects of a Diabetes Prevention Program on Type 2 Diabetes Risk Factors and Quality of Life Among Latino Youths With Prediabetes： A Randomized Clinical Trial［J］. JAMA Netw Open， 2022， 5（9）： e2231196. doi:10.1001/jamanetworkopen.2022.31196 doi: 10.1001/jamanetworkopen.2022.31196
[27]	DAVIES M J， D'ALESSIO D A， FRADKIN J， et al. Management of Hyperglycemia in Type 2 Diabetes， 2018. A Consensus Report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD）［J］. Diabetes Care， 2018， 41（12）： 2669-2701. doi:10.2337/dci18-0033 doi: 10.2337/dci18-0033
[28]	中华医学会内分泌学分会，中华医学会糖尿病学分会，中国医师协会内分泌代谢科医师分会，等. 中国成人糖尿病前期干预的专家共识（2023版）［J］. 中华糖尿病杂志， 2023， 15（6）： 484-494.
[29]	SPURR S， BALLY J， NALWOOGA N. Honoring the voices of families： An interpretive description of parents' understandings of， and insights into preventing type 2 diabetes in adolescents［J］. BMC Pediatr， 2022， 22（1）： 458. doi:10.1186/s12887-022-03487-9 doi: 10.1186/s12887-022-03487-9
[30]	AL-BADRI M， KILROY C L， SHAHAR J I， et al. In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity［J］. Ther Adv Endocrinol Metab， 2022， 13： 20420188221093220. doi:10.1177/20420188221093220 doi: 10.1177/20420188221093220
[31]	HAMDY O， CARVER C. The Why WAIT program： improving clinical outcomes through weight management in type 2 diabetes［J］. Curr Diab Rep， 2008， 8（5）： 413-420. doi:10.1007/s11892-008-0071-5 doi: 10.1007/s11892-008-0071-5
[32]	RUIZ-LEON A M， CASAS R， CASTRO-BARQUERO S， et al. Efficacy of a Mobile Health-Based Behavioral Treatment for Lifestyle Modification in Type 2 Diabetes Self-Management： Greenhabit Randomized Controlled Trial［J］. J Med Internet Res， 2025， 27： e58319. doi:10.2196/58319 doi: 10.2196/58319
[33]	KO J H， MOON S J， AJJAN R A， et al. Workplace-based continuous glucose monitoring with structured education for pre-diabetes and type 2 diabetes： A prospective community cohort study［J］. Diabetes Obes Metab， 2025， 27（6）： 2996-3005. doi:10.1111/dom.16304 doi: 10.1111/dom.16304
[34]	GREGG E W， CHEN H， WAGENKNECHT L E， et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes［J］. JAMA， 2012， 308（23）： 2489-2496. doi:10.1001/jama.2012.67929 doi: 10.1001/jama.2012.67929
[35]	KNOWLER W C， BARRETT-CONNOR E， FOWLER S E， et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin［J］. N Engl J Med， 2002， 346（6）： 393-403. doi:10.1056/nejmoa012512 doi: 10.1056/nejmoa012512
[36]	TUOMILEHTO J， LINDSTRÖM J， ERIKSSON J G， et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance ［J］. N Engl J Med， 2001， 344（18）： 1343-1350. doi:10.1056/nejm200105033441801 doi: 10.1056/nejm200105033441801
[37]	WHO. Diabetes ［M］. 2024-11-14.
[38]	American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes： Standards of Care in Diabetes-2025［J］. Diabetes Care， 2025， 48（1 ）： S167-s180. doi:10.2337/dc22-s008 doi: 10.2337/dc22-s008
[39]	中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）［J］. 中华糖尿病杂志， 2025， 17（1）： 16-139.
[40]	BANCKS M P， CHEN H， BALASUBRAMANYAM A， et al. Type 2 Diabetes Subgroups， Risk for Complications， and Differential Effects Due to an Intensive Lifestyle Intervention ［J］. Diabetes Care， 2021， 44（5）： 1203-1210. doi:10.2337/dc20-2372 doi: 10.2337/dc20-2372
[41]	WING R R， BOLIN P， BRANCATI F L， et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes ［J］. N Engl J Med， 2013， 369（2）： 145-154. doi:10.1056/nejmoa1212914 doi: 10.1056/nejmoa1212914
[42]	TAYLOR R， AL-MRABEH A， SATTAR N. Understanding the mechanisms of reversal of type 2 diabetes ［J］. Lancet Diabetes Endocrinol， 2019， 7（9）： 726-736. doi:10.1016/s2213-8587(19)30076-2 doi: 10.1016/s2213-8587(19)30076-2